Bone Health Technologies Awarded New Patent for Wearable Treatment for Osteopenia and Osteoporosis in Post-Menopausal Women 

Bone Health Technologies Awarded New Patent for Wearable Treatment for Osteopenia and Osteoporosis in Post-Menopausal Women 

First Device to Demonstrate Bone Strength Benefit in Clinical Trial

REDWOOD CITY, CA (DEC, 2023)– Bone Health Technologies (BHT), a leading innovator in health technologies to improve bone health, has been granted its fourth patent to further its commercialization of the Osteoboost device. Osteoboost has been shown in clinical trials to reduce the loss of bone mass in post-menopausal women. Public health data shows that most fragility fractures occur in patients with osteopenia, further emphasizing the urgent need for effective early interventions before patients progress to osteoporosis. 

The Osteoboost patent recognizes the invention as a wearable apparatus focused on the treatment or prevention of osteopenia or osteoporosis. It stimulates bone growth and preserves bone mineral density by sending low-frequency vibrations to the targeted area. The vibrating pieces are secured to the user laterally and are monitored and regulated via multiple accelerometers.

“Over 63 million Americans have low bone density, yet the field has been lacking new therapies with no new agents in clinical trials – innovations such as Osteoboost are critical to turning around the public health trajectory of fractures,” said Laura Yecies, CEO of Bone Health Technologies

“My motivation to invent a novel solution for low bone density resulted directly from my experience treating so many patients with painful vertebral compression fractures.  I was determined to develop a non-drug treatment that patients would be interested in using and could incorporate into their daily lives to prevent the loss of bone that results in fractures,” according to Dr. Shane Mangrum, Founder, Bone Health Technologies.

Recently, Bone Health Technologies filed for Class 2 Prescription De Novo Approval with the FDA and was previously awarded Breakthrough Device Status. BHT presented data from their clinical trial at ASBMR 2023 and ENDO 2023. The results of this double-blinded, sham-controlled design provided significant evidence supporting the efficacy of the Osteoboost in mitigating the decline of bone strength in post-menopausal women.

Bone Health Technologies is honored to be a recipient of an additional patent and is optimistic about future developments of the Osteoboost as they strive to continue forwarding their work.


Bone Health Technologies is a Redwood City-based company that applies science and medical expertise to create better health outcomes for women and men at risk of developing osteoporosis and associated bone fractures. Osteoboost is poised to become the new standard of care in treating both osteoporosis and osteopenia (the precursor to osteoporosis). Visit for more information.